Brian Metzger is an Infectious Disease physician. OpenAlex indexes 26 publications with 269 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1301 W 38th St
Suite 403
Austin, TX 787051000
Telephone
512-459-9710Registry record last updated 6 Jul 2009.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Cumberland Pharmaceuticals, Inc.Program year202519 payments
- Gilead Sciences, Inc.Program year202534 payments
- ViiV Healthcare CompanyProgram year202517 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Cephalosporin Antibacterial26%Cefazolin Sodium52%Ceftriaxone49%Part D<11 patientsFirst-generation cephalosporins18.1%Cephalexin100%Part D≥12 patients+ 8 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- P-1958. Efficacy and Safety of Rezafungin, A Long-Acting Echinocandin
Open Forum Infectious Diseases
2026 - P-374. Long-term Effectiveness of Long-Acting Cabotegravir and Rilpivirine in an Infectious Disease Office-Based HIV Program
Open Forum Infectious Diseases
2026 - 660. Early Experience with Use of Pemivibart for the Pre-exposure Prophylaxis of Coronavirus Disease 2019
Open Forum Infectious Diseases
2026 - P-1873. Telavancin Outcomes in Infections Treated with Outpatient Parenteral Antibiotic Therapy (OPAT)
Open Forum Infectious Diseases
2025
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”